title: Adiponectin and endothelial markers in postmenopausal women taking oral or transdermal hormone therapy.
abstract: OBJECTIVE
  To assess the concentration of adiponectin, soluble E-selectin, soluble thrombomodulin and tissue activator plasminogen antigen in postmenopausal women who received oral or transdermal hormone therapy.
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  Polish university hospitals.
  
  
  METHODS
  Seventy-six healthy postmenopausal women.
  
  
  METHODS
  Forty-six women who received oral (n = 26) or transdermal (n = 20) hormone therapy and a control group without such medication (n = 30), all aged 44-58 years.
  
  
  METHODS
  Plasma concentrations of adiponectin, soluble E-selectin, soluble thrombomodulin and tissue activator plasminogen antigen by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  We found a significantly higher concentration of adiponectin in women on oral and transdermal therapy in comparison to the control group and a significantly lower concentration of soluble E-selectin in women who received oral hormone therapy vs. the control group. A significantly higher concentration of tissue activator plasminogen antigen was obtained in the group of women using transdermal menopausal hormone therapy compared with those receiving oral therapy and with the control group.
  
  
  CONCLUSIONS
  Reduced levels of soluble E-selectin in women using menopausal hormone therapy could lead to reduction in the intensity of expression of the adhesion factors on the surface of the vascular endothelium. Menopausal hormone therapy might have advantageous effects on vascular endothelial function through adiponectin. Transdermal therapy may have adverse effects associated with elevated tissue activator plasminogen antigen levels and thereby the higher risk of ischemic heart disease.
authors.affiliation: Department of Pathophysiology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland. ruszkowska.basia@gmail.com
authors.forename: Barbara
authors.initials: B
authors.lastname: Ruszkowska
authors.forename: Alina
authors.initials: A
authors.lastname: Sokup
authors.forename: Arleta
authors.initials: A
authors.lastname: Kulwas
authors.forename: Justyna
authors.initials: J
authors.lastname: Kwapisz
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Góralczyk
authors.forename: Maciej W
authors.initials: MW
authors.lastname: Socha
authors.forename: Piotr
authors.initials: P
authors.lastname: Rhone
authors.forename: Danuta
authors.initials: D
authors.lastname: Rość
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D015415:Biomarkers / Q000097:blood; D004333:Drug Administration Routes; D019040:E-Selectin / Q000097:blood*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism*; D017698:Postmenopause / Q000097:blood / Q000187:drug effects*; D018180:Thrombomodulin / Q000097:blood*
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D019040:E-Selectin; C546931:THBD protein, human; D018180:Thrombomodulin; D010958:Plasminogen